Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Kikkoman Biochemifa Company advances global health and safety through precision-driven innovation in biotech and food testing.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    granules-india-limited-m-2025-07-07

    Virtual Booth

    Contact Supplier

    Allsino Pharma excels in R&D & manufacturing of RSMs, GMP intermediates, & APIs; ISO-certified, GMP-compliant, accredited by NMPA.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Menu

    Romosozumab

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    3D modelling of hip DXA reveals improvements in bone density of romosozumab
    3D modelling of hip DXA reveals improvements in bone density of romosozumab

    09 Sep 2022

    // UCB

    https://www.ucb.com/stories-media/Press-Releases/article/ASBMR-2022-3D-modelling-of-hip-DXA-scans-in-postmenopausal-women-with-osteoporosis-reveals-superior-improvements-in-bone-density-of-romosozumab-versus-controls

    UCB
    09 Sep 2022
    Share Share
    Romosozumab substantially builds bone density in hip and spine
    Romosozumab substantially builds bone density in hip and spine

    11 Nov 2020

    // EUREKALERT

    https://www.eurekalert.org/pub_releases/2020-11/acor-rsb110520.php

    EUREKALERT
    11 Nov 2020
    Share Share
    Romosozumab for the treatment of osteoporosis
    Romosozumab for the treatment of osteoporosis

    15 Jun 2020

    // SCIENCEDIRECT

    https://www.sciencedirect.com/science/article/pii/S2405525518300062

    SCIENCEDIRECT
    15 Jun 2020
    Share Share
    UCB Shares Breadth of Innovative New Data from Rheumatology for EULAR 2020
    UCB Shares Breadth of Innovative New Data from Rheumatology for EULAR 2020

    04 Jun 2020

    // UCB

    https://www.ucb.com/stories-media/Press-Releases/article/UCB-Shares-Breadth-of-Innovative-New-Data-from-Rheumatology-Portfolio-for-EULAR-2020-E-Congress

    UCB
    04 Jun 2020
    Share Share
    Amgen studying Otezla for coronavirus, Q1 results beat estimates
    Amgen studying Otezla for coronavirus, Q1 results beat estimates

    02 May 2020

    // PRESS RELEASE

    http://investors.amgen.com/news-releases/news-release-details/amgen-reports-first-quarter-2020-financial-results/

    PRESS RELEASE
    02 May 2020
    Share Share
    Amgen EVENITY (Romosozumab-aqqg Injection) Receives Supplemental Approval in US
    Amgen EVENITY (Romosozumab-aqqg Injection) Receives Supplemental Approval in US

    21 Dec 2019

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761062

    FDA
    21 Dec 2019
    Share Share